Hanmi Pharmaceutical's Eppe could launch in Korea before year-end at an estimated 150,000 won for four weeks, 45% below Mounjaro's cheapest listing. Lilly won about 85% of the market at a higher price than Wegovy, so Novo, which has cut once already, is the likelier incumbent to cut again.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+25
- Incentives
- Insufficient
- Confidence40
Retatrutide's 12 mg dose cut body weight 25% over 80 weeks, versus 3.9% on placebo, in a 2,339-adult phase 3 trial in NEJM. Its near-30% two-year figure comes from 532 completers, and because placebo was the only comparator, the trial cannot rank the drug against Ozempic.
Reality
- Evidence65
- Adoption
- Insufficient
- Hype gap+20
- Incentives70
- Confidence60
Eli Lilly's 367-person trial found the top dose of tirzepatide plus eloralintide cut body weight 23.3%, against 14.8% on tirzepatide alone. Dropout ran far higher on the combination, so nobody has yet measured how much of that gain holds across everyone prescribed the pair.
Reality
- Evidence60
- Adoption
- Insufficient
- Hype gap+30
- Incentives65
- Confidence55
AriBio's October Phase 3 readout for AR1001 decides whether Fosun Pharma adds $80 million to the $60 million option fee it paid in May. Among the Korean biotech events due that month, it is the one that ties a partner's cash directly to trial data.
Reality
- Evidence40
- Adoption
- Insufficient
- Hype gap+20
- Incentives70
- Confidence45
Regeneron's Otarmeni won FDA approval in April as the first gene therapy for hearing loss, with 42 percent of 24 treated children since regaining hearing. The deafness it treats leaves the rest of the ear intact. How far the approach can reach beyond this one gene is still unknown.
Reality
- Evidence58
- Adoption
- Insufficient
- Hype gap+10
- Incentives
- Insufficient
- Confidence52
Eli Lilly's retatrutide cut body weight by more than 20% on average at its top dose in an 80-week phase 3 trial of 1,152 people with type 2 diabetes. Lilly calls that a first for the field, and it gives the four- and five-receptor drugs now in development a figure to beat in patients with diabetes.
Reality
- Evidence68
- Adoption
- Insufficient
- Hype gap+12
- Incentives72
- Confidence62
Jurors found Eli Lilly broke good faith in ending its rezpeg deal with Nektar Therapeutics and awarded Nektar $90 million plus interest. Nektar's shares still fell about 4% on Friday as investors set the award against a far larger ask.
Reality
- Evidence62
- Adoption
- Insufficient
- Hype gap0
- Incentives50
- Confidence64
One personal injury firm has filed more than 90 New Jersey suits claiming Novo Nordisk's Ozempic and Wegovy caused sudden vision loss. Denmark has awarded about $55,600 a patient for the same injury, the only price on record, while studies of whether the drugs cause it still disagree.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+10
- Incentives65
- Confidence50
UT Austin, Eli Lilly and Boston University found a Tris buffer keeps mRNA nanoparticles potent through freezing, where citrate cannot. Only 5% to 10% of an mRNA dose reaches its target, so the storage solution shapes how much material a patient needs.
Reality
- Evidence50
- Adoption
- Insufficient
- Hype gap+25
- Incentives45
- Confidence50
Existing holders are selling 36.5 million of the 50 million shares on offer. Oura's own 13.5 million would net about $532.6 million at the $42 midpoint, ahead of pricing on September 29 at up to $14.1 billion.
Perspective Coverage
5 publishers
- Builder
- Builder 19%
- Operator
- Operator 22%
- Investor
- Investor 59%
Reality
- Evidence72
- Adoption78
- Hype gap+18
- Incentives76
- Confidence68
Oura is selling 13.5 million of the 50 million shares on offer, so about $594m of the base deal reaches the company and 73% of it goes to people who already own stock. The subscription is what is being priced.
Reality
- Evidence72
- Adoption68
- Hype gap+14
- Incentives82
- Confidence64
The 2035 diversification target Novo gave investors in London is a single risk-adjusted total that includes assets already in the pipeline, and the launch list it published for 2027 through 2030 is almost all GLP-1 and amylin.
Reality
- Evidence64
- Adoption34
- Hype gap+24
- Incentives80
- Confidence67
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
- Evidence45
- Adoption74
- Hype gap+14
- Incentives62
- Confidence42
More than 90 New Jersey suits and dozens more against Novo Nordisk and Eli Lilly turn on a warning the FDA has not written while four other jurisdictions added theirs. Denmark's payouts are the only money that has moved so far.
Reality
- Evidence45
- Adoption55
- Hype gap+20
- Incentives65
- Confidence45
A Phase I dose-selection study put brenipatide's half-life at 9 to 12.5 days. Lilly says that supports once-weekly dosing in the Phase III trials it is now running in major depressive disorder and alcohol use disorder.
Reality
- Evidence45
- Adoption25
- Hype gap+35
- Incentives82
- Confidence58
Palomar Labs' first spinout is built on a molecule whose parent compound was tested in the 1970s and documented not to be hallucinogenic. Apathy affects about 40% of people with Parkinson's, and no drug is approved for it.
Reality
- Evidence40
- Adoption8
- Hype gap+35
- Incentives82
- Confidence42
Congress capped Medicare insulin at $35 a month, and 27 states plus Washington DC added out-of-pocket limits of their own. Two separate 2024 surveys still put the share of insulin users rationing the drug near a third.
Reality
- Evidence66
- Adoption52
- Hype gap+15
- Incentives58
- Confidence60
The Danish drugmaker will test Anthropic's science workbench on specific R&D workflows while an earlier company-wide OpenAI agreement keeps running alongside it. Bloomberg reported that financial terms were not disclosed.
Reality
- Evidence52
- Adoption22
- Hype gap+45
- Incentives82
- Confidence58
Semaglutide's approval starts above age 12 and tirzepatide's obesity approval at 18, but a published study and one Dallas hospital's own count both show children under 12 already taking these drugs, mostly for obesity and type 2 diabetes.
Reality
- Evidence48
- Adoption52
- Hype gap+15
- Incentives62
- Confidence45
Emmanuel Mignot and Masashi Yanagisawa reached the same wakefulness peptide from opposite directions. The drug class that followed now holds one narcolepsy approval and a much larger set of untested hopes.
Reality
- Evidence78
- Adoption52
- Hype gap+12
- Incentives40
- Confidence74